These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 36769040)

  • 1. CD123 a Therapeutic Target for Acute Myeloid Leukemia and Blastic Plasmocytoid Dendritic Neoplasm.
    Pelosi E; Castelli G; Testa U
    Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tagraxofusp, a first-in-class CD123-targeted agent: Five-year postapproval comprehensive review of the literature.
    Jen WY; Konopleva M; Pemmaraju N
    Cancer; 2024 Jul; 130(13):2260-2271. PubMed ID: 38620053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies.
    Testa U; Pelosi E; Castelli G
    Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31547472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the alpha subunit of IL-3 receptor (CD123) in patients with acute leukemia.
    Aldoss I; Clark M; Song JY; Pullarkat V
    Hum Vaccin Immunother; 2020 Oct; 16(10):2341-2348. PubMed ID: 32692611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapies Targeting CD123 for Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Xue T; Budde LE
    Hematol Oncol Clin North Am; 2020 Jun; 34(3):575-587. PubMed ID: 32336421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD123 as a Biomarker in Hematolymphoid Malignancies: Principles of Detection and Targeted Therapies.
    El Achi H; Dupont E; Paul S; Khoury JD
    Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33113953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Jain A; Sweet K
    J Natl Compr Canc Netw; 2023 May; 21(5):515-521. PubMed ID: 37156483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD123 and More: How to Target the Cell Surface of Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Bôle-Richard E; Pemmaraju N; Caël B; Daguindau E; Lane AA
    Cancers (Basel); 2022 May; 14(9):. PubMed ID: 35565416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance.
    Togami K; Pastika T; Stephansky J; Ghandi M; Christie AL; Jones KL; Johnson CA; Lindsay RW; Brooks CL; Letai A; Craig JW; Pozdnyakova O; Weinstock DM; Montero J; Aster JC; Johannessen CM; Lane AA
    J Clin Invest; 2019 Nov; 129(11):5005-5019. PubMed ID: 31437130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting CD123 in BPDCN: an emerging field.
    DiPippo AJ; Wilson NR; Pemmaraju N
    Expert Rev Hematol; 2021 Nov; 14(11):993-1004. PubMed ID: 34607517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting CD123 in AML.
    Lane AA
    Clin Lymphoma Myeloma Leuk; 2020 Sep; 20 Suppl 1():S67-S68. PubMed ID: 32862874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies.
    Testa U; Pelosi E; Frankel A
    Biomark Res; 2014 Feb; 2(1):4. PubMed ID: 24513123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells.
    Kovtun Y; Jones GE; Adams S; Harvey L; Audette CA; Wilhelm A; Bai C; Rui L; Laleau R; Liu F; Ab O; Setiady Y; Yoder NC; Goldmacher VS; Chari RVJ; Pinkas J; Chittenden T
    Blood Adv; 2018 Apr; 2(8):848-858. PubMed ID: 29661755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breakthrough in Blastic Plasmacytoid Dendritic Cell Neoplasm Cancer Therapy Owing to Precision Targeting of CD123.
    Zanotta S; Galati D; De Filippi R; Pinto A
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD123 bi-specific antibodies in development in AML: What do we know so far?
    Slade MJ; Uy GL
    Best Pract Res Clin Haematol; 2020 Dec; 33(4):101219. PubMed ID: 33279175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm.
    Lee SS; McCue D; Pemmaraju N
    Expert Rev Anticancer Ther; 2020 Jul; 20(7):543-550. PubMed ID: 32460559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells.
    Cai T; Gouble A; Black KL; Skwarska A; Naqvi AS; Taylor D; Zhao M; Yuan Q; Sugita M; Zhang Q; Galetto R; Filipe S; Cavazos A; Han L; Kuruvilla V; Ma H; Weng C; Liu CG; Liu X; Konoplev S; Gu J; Tang G; Su X; Al-Atrash G; Ciurea S; Neelapu SS; Lane AA; Kantarjian H; Guzman ML; Pemmaraju N; Smith J; Thomas-Tikhonenko A; Konopleva M
    Nat Commun; 2022 Apr; 13(1):2228. PubMed ID: 35484100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid Leukemia.
    Venugopal S; Daver N; Ravandi F
    Curr Hematol Malig Rep; 2021 Feb; 16(1):89-96. PubMed ID: 33630233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasm.
    Economides MP; McCue D; Lane AA; Pemmaraju N
    Expert Rev Clin Pharmacol; 2019 Oct; 12(10):941-946. PubMed ID: 31465247
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluating tagraxofusp for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).
    Wilson NR; Pemmaraju N
    Expert Opin Pharmacother; 2022 Mar; 23(4):431-438. PubMed ID: 35060807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.